Skip to main content
. 2018 May 29;6(3):370–388.e3. doi: 10.1016/j.jcmgh.2018.05.008

Figure 1.

Figure 1

High stool PA is a frequent adverse effect of ABx treatment in patients and impairs the epithelial barrier ex vivo. (A) Serine protease activity in stool-supernatant of patients before and after ABx treatment. Red line (n = 9), fluoroquinolone (+imidazole) antibiotic; blue line (n = 7), β-lactam antibiotic; green line (n = 4), cephalosporin (+macrolide) antibiotic; black line (n = 12), rifamycine antibiotic. (B) Staining of active serine proteases in stool-supernatants of patients before and after ABx treatment (TAMRA-FP sodium dodecyl sulfate–polyacrylamide gel electrophoresis). (C) Fluorescein translocation and TEER in polarized PTK6 cells on apical exposure to stool-supernatants from the same patient before versus after the respective ABx treatment ± PMSF-inhibition.